<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053910</url>
  </required_header>
  <id_info>
    <org_study_id>HOE498_4099</org_study_id>
    <nct_id>NCT01053910</nct_id>
  </id_info>
  <brief_title>Ramipril 10 mg/Day Prevention</brief_title>
  <official_title>A Multicentre Open, Non Comparative Study of the Safety of Ramipril (Tritace) 10 mg/Day in Prevention of Cardiovascular Events in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      The objective is to investigate the safety of ramipril 10 mg/day used in prevention of
      cardiovascular events in high-risk patients, including the criteria of the HOPE study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2003</start_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patient reaching the 10mg/day dose level</measure>
    <time_frame>30 days after the treatment start</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall number of adverse events</measure>
    <time_frame>at day 7 (visit 2), day 15 (visit 3), day 30 (visit 4), day 45 (visit 5) and day 60 (final visit)</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1012</enrollment>
  <condition>Atherosclerosis</condition>
  <arm_group>
    <arm_group_label>Ramipril</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Duration of treatment: 2 months 7 first days: 1.25mg once daily in patients with stable heart failure and 7 days 2.5mg once daily or 14 first days:2.5mg once daily in patients without heart failure for 14 more days:5mg once daily maintenance therapy for 1 month: 10 mg (5mg, 2 tablets)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramipril</intervention_name>
    <description>tablet of Ramipril once daily</description>
    <arm_group_label>Ramipril</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  History of coronary artery disease,

          -  Stroke

          -  Stable heart failure

          -  Peripheral vascular disease, or diabetes with at least one other cardiovascular risk
             factor (hypertension, elevated total cholesterol levels, low high-density lipoprotein
             cholesterol levels, cigarette smoking, or documented microalbuminuria).

        Exclusion Criteria:

          -  Non stabilized or NYHA grade IV heart failure patients

          -  Hemodynamically significant primary valvular or outflow tract obstruction (eg. mitral
             valve stenosis, asymmetric septal hypertrophy, malfunctioning prosthetic valve)

          -  Constrictive pericarditis.

          -  Complex congenital heart disease.

          -  Syncopal episodes presumed to be due to uncontrolled life-threatening arrhythmias
             (asymptomatic cardiac arrhythmias including ventricular tachycardia are not an
             exclusion criterion).

          -  Planned cardiac surgery or angioplasty within 3 months (patient may be reconsidered
             for the trial after the procedure).

          -  Cor pulmonale.

          -  Heart transplant recipient.

          -  Significant renal disease defined as:

               -  Renal artery stenosis;

               -  Creatine clearance &lt;0.6 ml/second or serum creatinine≥ 200 mEq/L (≥2.26 mg/dl)

               -  Overt nephropathy: ≥1 plus proteinuria on dipstick or urinary albumin excretion &gt;
                  200 micrograms/minute (300 mg/24 hrs)

               -  Hyperkalemia; K&gt;5.5 mEq/L.

          -  Patient is simultaneously taking another experimental drug.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rezaul Farid Khan, Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Dhaka</city>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <last_update_submitted>January 20, 2010</last_update_submitted>
  <last_update_submitted_qc>January 20, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramipril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

